The US biotech firm BioMarin Pharmaceutical has agreed a cooperation with DiNAQOR AG based in Pfäffikon. The aim here is to develop new treatments for rare, genetic myocardial disorders. Within the framework of this partnership, BioMarin has also acquired a license for the preclinical program DiNA-001 from DiNAQOR. This focuses on the gene MYBPC3, a mutation of which plays a decisive role in certain myocardial diseases.
According to a press release, DiNAQOR will receive an upfront payment in an undisclosed amount. Moreover, milestone payments in recognition of major successes in addition to multi-tiered royalty payments on product sales have been included in the agreement.
DiNAQOR was founded in 2019 by a group of several biotech and pharma experts. In addition to the headquarters in Pfäffikon, the company also maintains a presence in the USA and the UK. DiNA-001 is the company’s leading therapy candidate.
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space